Caplyta (lumateperone) Letter of Medical Necessity
Caplyta (lumateperone) typically requires step therapy through generic atypical antipsychotics. LMNs should address tolerability concerns or specific clinical needs.
FDA-Approved Indications
- ● schizophrenia in adults
- ● depressive episodes associated with bipolar I or II disorder
Why Caplyta Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy through preferred atypicals
- 2. Indication not specified
- 3. Generic atypical not tried
What to Include in a Caplyta Letter of Medical Necessity
Document diagnosis, prior antipsychotic trials with reasons for discontinuation (efficacy, EPS, metabolic, sedation), and clinical rationale for lumateperone.
Key clinical evidence to cite:
- ✓ Studies 005, 301, 302, 401, 404
Relevant guidelines:
- 📖 APA Schizophrenia Guideline
Caplyta Prior Authorization Criteria
Standard criteria across major US payers for Caplyta. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy through preferred atypicals
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Caplyta
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Caplyta Prior Authorization FAQ
Why was my Caplyta prior authorization denied?
The most common denial reasons for Caplyta are: Step therapy through preferred atypicals; Indication not specified; Generic atypical not tried.
What should a Caplyta Letter of Medical Necessity include?
Document diagnosis, prior antipsychotic trials with reasons for discontinuation (efficacy, EPS, metabolic, sedation), and clinical rationale for lumateperone.
Which payers cover Caplyta?
Caplyta is covered by major US payers including UnitedHealthcare, Aetna, Cigna, CVS Caremark, Medicare Part D, though formulary tier and prior authorization criteria vary.